Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.

Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making. An analysis of 10 years of decision-making by health ...

PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with ...

On this day 22 years ago, Comparator Systems stock gained 3,025 percent and set a new record for single-day Nasdaq trading volume. Where The Market Was The Dow finished the day at 5,475.14. The S&P ...

There’s an inside joke among cyclists – the number of bikes you need is “n+1”, where “n” is your current number of bikes. The same probably also applies to the number of tools and equipment a hacker ...

Editor’s note: PhD candidate, Seyyed Hossein Pishgar approached me with this paper, which I believe has some unique and creative circuitry and architectures. I have ...